Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity

Clinical Rheumatology

Volumn 36, Issue 2, 2017, Pages 381-390

  Michelfelder, M ^a,b   Becker, M ^b,c   Riedlinger, A ^d   Siegert, E ^b   Dromann D ^e   Yu, X ^f   Petersen, F ^f   Riemekasten, G ^b,e,f  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Asklepios Fachklinikum Teupitz ^*  (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Interstitial lung disease; Mortality; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

ANGIOTENSIN; AUTOANTIBODY; CARBON MONOXIDE; ENDOTHELIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; MALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; SYSTEMIC SCLEROSIS; AGED; CHEMISTRY; COMPLICATION; EXERCISE TOLERANCE; HEMODYNAMICS; KAPLAN MEIER METHOD; LUNG; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; AUTOANTIBODIES; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 85007442988     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3504-6     Document Type: Article

References (45)

1. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940–944
2. Chang B, Wigley FM, White B, Wise RA (2003) Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 30:2398–2405
3. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792–3800
4. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS et al (2005) Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 32:1273–1278
5. de Azevedo AB, Sampaio-Barros PD, Torres RM, Moreira C (2005) Prevalence of pulmonary hypertension in systemic sclerosis. Clin Exp Rheumatol 23:447–454
6. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M et al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 47:1185–1192
7. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J et al (2009) Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 48:304–308
8. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J et al (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39:682–691
9. Vonk MC, Broers B, Heijdra YF, Ton E, Snijder R, van Dijk AP et al (2009) Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 68:961–965
10. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P et al (2010) Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 37:2290–2298
11. Bauer PR, Schiavo DN, Osborn TG, Levin DL, St Sauver J, Hanson AC et al (2013) Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 144:571–577
12. Della Rossa A, Valentini G, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 60:585–591
13. White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 29:371–390
14. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184–191
15. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151–157
16. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM et al (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569–577
17. Behr J, Ryu JH (2008) Pulmonary hypertension in interstitial lung disease. Eur Respir J 31:1357–1367
18. Bals R, Vogelmeier C (2006) Lungenfibrose. In: Siegenthaler W, Blum HE (eds) Klinische Pathophysiologie. Thieme, Stuttgart, pp. 775–776
19. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537
20. Fischer A, Swigris JJ, Bolster MB, Chung L, Csuka ME, Domsic R et al (2014) Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 32:S-109–S-114
21. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35:765–770
22. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746–752
23. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492
24. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX et al (2002) Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106:319–324
25. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD et al (2006) Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 174:803–809
26. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM (2006) Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:659–664
27. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G (2006) Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27:589–595
28. Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H et al (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70:530–536
29. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C et al (2014) Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190:808–817
30. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576
31. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755
32. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A et al (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189–194
33. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43–S54
34. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66
35. Halpern SD, Taichman DB (2009) Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 136:37–43
36. Rich S (1988) Primary pulmonary hypertension. Prog Cardiovasc Dis 31:205–238
37. Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65:1336–1340
38. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV et al (2007) Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 66:1467–1472
39. The EULAR Scleroderma Trials and Research group (EUSTAR) (2008) The EUSTAR-database – Project description. Available from: http://www.eustar.org/application/EUSTAR cohort description UW 14.01.08 English version.doc. Internet. Accessed 12 Oct 2016
40. Hanley JA (1989) Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 29:307–335
41. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088–1093
42. Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203
43. Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M et al (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16:R29
44. Manning HL, Mahler DA (2001) Pathophysiology of dyspnea. Monaldi Arch Chest Dis 56:325–330
45. Gunther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E et al (2014) Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 16:R65